All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 24, 2022
Home » Newsletters » BioWorld Asia

BioWorld Asia

May 17, 2022

View Archived Issues
China U.S. deal

Merck acquires global rights to cancer drug from Kelun in $1.4B deal

In a deal potentially worth more than $1.4 billion, Sichuan Kelun Pharmaceutical Co. Ltd. has out-licensed a large molecule drug in cancer to Merck & Co. Inc. for development and commercialization outside mainland China, Hong Kong, Macao, and Taiwan. Read More

F2G finds partner for antifungal olorofim in $480M Shionogi deal

Antifungals specialist F2G Ltd. has signed an agreement with Japanese pharma Shionogi & Co. Ltd. for development and commercialization of its treatment for invasive aspergillosis in both Asia and Europe. Under the terms of the deal, F2G is getting $100 million up front and regulatory and commercialization milestones of up to $380 million. The two partners will share clinical development costs. Read More
Concept of business partnership

Taiho goes Pearl diving, brings up $405M Cullinan deal

Cullinan Oncology Inc.’s lead program deal with Otsuka Holdings Co. Ltd. subsidiary Taiho Pharmaceutical Co. Ltd. brings $275 million up front and the potential for as much as $130 million in regulatory milestone payments. Read More
Eye exam

Zhaoke licenses Asian rights to Visus presbyopia candidates in $130M deal

Visus Therapeutics Inc. has out-licensed phase III candidates Brimochol and Carbachol to Hong Kong’s Zhaoke Ophthalmology Ltd. to develop and commercialize its long-acting, presbyopia-correcting eye drops in greater China, South Korea and select Southeast Asian territories. Read More
Global vaccine.png

Zhifei Lvzhu wins rights to whooping cough vaccine from Intravacc

Beijing Zhifei Lvzhu Biopharmaceutical Co. Ltd. has picked up rights to a whooping cough vaccine candidate from Intravacc B.V. on undisclosed terms. Zhifei Lvzhu gained exclusive rights to develop and commercialize the vaccine in China, as well as nonexclusive rights in Africa, South America, and selected Asian countries. In turn, Intravacc is eligible to receive milestone and up-front payments plus royalties on net sales of the vaccine, should it reach market. Read More
seoul korea

BioKorea 2022: As microbiome therapies emerge, leaders see challenges, opportunities

Microbiome-modulating therapies are increasingly being explored to treat a variety of diseases. However, the market is still in its infancy and a lack of solid regulations remains challenging for companies to overcome, speakers at the BioKorea 2022 said May 11. Read More
Oral medication

Orion picks up rights to Jemincare non-opioid pain drug in €15M deal

Orion Corp. has secured exclusive global rights, outside China, to a non-opioid pain drug candidate from Jiangxi Jemincare Group Co. Ltd. The deal, for oral sodium channel inhibitor JMKX-000623, brought Jemincare €15 million (US$15.6 million) up front.  Read More

BioKorea 2022: Key to predicting next pandemic lies in infectious diseases’ zoonotic component

As the COVID-19 pandemic slowly starts to ease globally, efforts are already gearing up to predict the next potential pandemic. One institute researching the increasing number of diseases transmitted from animals to humans is Canada’s Vaccine and Infectious Disease Organization, part of the University of Saskatchewan. Read More
Cancer cells being destroyed by immunotherapy

The trouble with TIGITs: Genentech’s failure sparks worry across class

A phase III failure for Roche Holding AG unit Genentech Inc.'s anti-TIGIT immunotherapy tiragolumab dragged down the share value of several other class entrants.  Read More

Appointments and advancements for May 17, 2022

New hires and promotions in the biopharma industry in Asia-Pacific, including: Aum, Canbridge, Hutchmed. Read More

In the clinic for May 10-16, 2022

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Adocia, Akston, Bio-Thera Solutions, Bridge, Carsgen, Clinuvel, Dizal, Hua Medicine, Hyundai, Inovio, Lianbio, Tonghua Dongbao, Zhimeng. Read More

Other news to note for May 17, 2022

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Akebia, Anges, Apirx Pharmaceuticals USA, Aum, Bioasis, Celsion, Clinton Health Access Initiative, CSL, Dyadic International, Eiger, Incannex Healthcare, Institute for Clinical and Economic Review, Merck, Modex, Neuramedy, Opko Health, Otsuka, Pfizer, Propanc, Roche, Sound, Vifor, Visus, Zhaoke Ophthalmology. Read More

Regulatory actions for May 10-16, 2022

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Ascletis, Eisai, Eli Lilly, Elpiscience, Gilead Sciences, Immuron, Incyte, Kadmon, Moleculin, Resverlogix, Therapeutic Solutions International, Turning Point, Very, Yiling, Zai Lab. Read More

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for May 23.
  • China U.S. deal

    Merck acquires global rights to cancer drug from Kelun in $1.4B deal

    BioWorld
    In a deal potentially worth more than $1.4 billion, Sichuan Kelun Pharmaceutical Co. Ltd. has out-licensed a large molecule drug in cancer to Merck & Co. Inc. for...
  • Lung cancer illustration

    Acea Pharma fails to win green light for abivertinib in China

    BioWorld
    Zhejiang Acea Pharmaceutical Co. Ltd. failed to obtain marketing approval from China’s NMPA for its third-generation EGFR tyrosine kinase inhibitor, abivertinib....
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing